

## SUPPLEMENTAL MATERIAL

Supplemental Table 1: Plasma Angiogenic and Inflammatory Peptides

Peptide (pg/ml)	Control n=19		IVC n=22			PA n=22		
<b>Activin A</b>	9,987	± 13,518	4,260	± 3,791		3,834	± 3,010	
<b>AgRP</b>	383	± 936	77	± 88		63	± 54	
<b>Angiopoietin-1</b>	39,529	± 34,795	14,398	± 9,565	*	10,486	± 7,298	* t
<b>Angiopoietin-2</b>	898	± 485	2,927	± 1,917	*	2,747	± 2,149	*
<b>Angiogenin</b>	1,455	± 275	1,754	± 732		1,644	± 955	
<b>Angiostatin</b>	605,394	± 381,575	189,129	± 243,684	*	152,655	± 176,598	*
<b>ANGPTL4</b>	24,190	± 37,241	22,317	± 31,030		18,799	± 22,062	
<b>bFGF</b>	248	± 228	49	± 42		160	± 559	
<b>CXCL16</b>	834	± 635	981	± 372		819	± 294	t
<b>EGF</b>	40	± 44	22	± 16		24	± 31	
<b>ENA-78</b>	6,991	± 9,404	4,032	± 3,242		3,885	± 3,187	
<b>FGF-4</b>	7,247	± 8,739	6,181	± 4,812		4,836	± 3,483	
<b>Follistatin</b>	14,593	± 15,420	19,194	± 19,315		16,306	± 14,028	
<b>G-CSF</b>	191	± 219	78	± 117		47	± 37	*
<b>GM-CSF</b>	50	± 126	6	± 13		6	± 13	
<b>GRO</b>	1,687	± 1,608	970	± 638		837	± 415	
<b>HB-EGF</b>	31	± 36	3	± 3	*	3	± 2	*
<b>HGF</b>	862	± 685	9,817	± 10,086	*	9,323	± 7,112	*
<b>I-309</b>	82	± 115	57	± 37		50	± 32	
<b>I-TAC</b>	345	± 387	856	± 618	*	632	± 421	
<b>IFNg</b>	301	± 285	37	± 27	*	31	± 20	*
<b>IGF-I</b>	164,041	± 536,525	12,879	± 14,578		7,601	± 8,060	
<b>IL- 1a</b>	156	± 402	21	± 21		19	± 20	
<b>IL- 1b</b>	368	± 499	255	± 196		213	± 150	
<b>IL- 2</b>	95	± 60	18	± 19	*	14	± 14	*
<b>IL- 4</b>	203	± 411	68	± 57		52	± 34	
<b>IL- 6</b>	81	± 85	21	± 16	*	17	± 16	*
<b>IL- 8</b>	85	± 52	19	± 16	*	20	± 17	*
<b>IL-10</b>	18	± 47	4	± 3		5	± 7	
<b>IL-12p40</b>	774	± 876	526	± 337		485	± 305	
<b>IL-12p70</b>	13	± 25	3	± 2		4	± 4	
<b>IL-17</b>	224	± 164	25	± 21	*	30	± 24	*
<b>IP-10</b>	52	± 64	52	± 40		67	± 63	
<b>Leptin</b>	1,661	± 1,620	786	± 577		790	± 454	
<b>LIF</b>	385	± 345	147	± 64	*	191	± 80	* t
<b>MCP-1</b>	157	± 111	160	± 100		168	± 104	
<b>MCP-2</b>	144	± 176	116	± 94		93	± 69	
<b>MCP-3</b>	311	± 192	295	± 271		288	± 263	

<b>MCP-4</b>	1,207 ± 1,606	883 ± 809	697 ± 484
<b>MMP-1</b>	7,050 ± 9,554	6,126 ± 4,802	5,734 ± 4,332
<b>MMP-9</b>	41,294 ± 33,788	44,676 ± 61,978	35,245 ± 25,408
<b>PDGF-BB</b>	2,466 ± 987	1,418 ± 568	1,490 ± 749
<b>PECAM-1</b>	13,752 ± 11,124	47,860 ± 133,038	42,050 ± 104,621
<b>PIGF</b>	57 ± 47	33 ± 23	43 ± 22
<b>RANTES</b>	1,853 ± 314	2,221 ± 598	2,219 ± 441
<b>TGF<math>\alpha</math></b>	584 ± 2,127	139 ± 180	95 ± 98
<b>TGF<math>\beta</math>1</b>	11,537 ± 29,920	1,585 ± 2,899	1,797 ± 2,311
<b>TGF<math>\beta</math>3</b>	86 ± 98	82 ± 63	78 ± 54
<b>Tie-1</b>	6,012 ± 8,554	2,479 ± 2,783	3,642 ± 5,565
<b>Tie-2</b>	1,545 ± 1,767	1,164 ± 893	1,265 ± 1,151
<b>TIMP-1</b>	141,815 ± 35,791	126,815 ± 49,143	116,066 ± 46,476
<b>TIMP-2</b>	66,926 ± 24,963	47,205 ± 32,353	40,760 ± 18,820
<b>TNF<math>\alpha</math></b>	1,429 ± 2,199	99 ± 144	102 ± 106
<b>TNF<math>\beta</math></b>	141 ± 229	8 ± 13	7 ± 12
<b>TPO</b>	5,676 ± 4,393	1,636 ± 1,205	1,711 ± 1,143
<b>uPAR</b>	20,499 ± 19,329	12,644 ± 14,083	10,972 ± 7,676
<b>VEGF</b>	3,348 ± 2,518	725 ± 703	604 ± 589
<b>VEGF R2</b>	9,724 ± 11,293	9,319 ± 5,332	9,062 ± 5,147
<b>VEGF R3</b>	3,243 ± 4,070	2,049 ± 1,647	2,187 ± 1,373
<b>VEGF-D</b>	716 ± 908	642 ± 518	742 ± 704

Data presented as mean  $\pm$  standard deviation; \*p<0.01, versus control; †p<0.01, versus IVC; AgRP, Agouti-related peptide; ANGPTL, angiopoietin-like; bFGF, basic fibroblast growth factor; CXCL, C-X-C motif ligand; EGF, epidermal growth factor; ENA, epithelial-derived neutrophil-activating peptide; FGF, fibroblast growth factor; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; GRO, growth related oncogene; HB-EGF, heparin-binding epidermal growth factor; HGF, hepatocyte growth factor; I-TAC, interferon-inducible T-cell alpha chemoattractant; IFN $\gamma$ , interferon gamma; IL, interleukin; IP, interferon-gamma-induced protein; LIF, leukemia inhibitory factor; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinase; PDGF-BB, platelet derived growth factor BB subunits; PECAM, platelet endothelial cell adhesion molecule; PIGF, phosphatidylinositol-glycan class F; RANTES, regulated on activation normal T-cell expressed and secreted; TGF, transforming growth factor; Tie, tyrosine kinase with immunoglobulin-like and EGF-like domains; TIMP, tissue inhibitor matrix metalloproteinase; TNF, tissue necrosis factor; TPO, thrombopoietin; uPAR, urokinase plasminogen activator receptor; VEGF, vascular endothelial growth factor; IVC, inferior vena cava; PA, pulmonary artery; SD, standard deviation